Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1.

Qiuxia Cui,Huan Fang,Wenlong Ren,Huichun Liang,Wenjing Liu,Xue Liu,Chuanyu Yang,Jing Feng,Xinye Wang,Ceshi Chen,Yujie Shi

doi:10.7554/elife.88483

Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1.

Qiuxia Cui, Huan Fang + Show 9 more

Open Access

https://doi.org/10.7554/elife.88483

Copy DOI

Journal: eLife	Publication Date: Oct 3, 2023
Citations: 2	License type: CC BY 4.0

Affiliation: Guangdong Medical College, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Kunming Institute of Zoology, University of Science and Technology of China, Shanghai University of Medicine and Health Sciences, Southern Medical University, Chinese University of Hong Kong, Sixth Affiliated Hospital of Kunming Medical University, Kunming Medical University, Henan Provincial People's Hospital

#Drug Resistance In Triple-negative Breast Cancer #Resistance In Triple-negative Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Anti-tumor drug resistance is a challenge for human triple-negative breast cancer (TNBC) treatment. Our previous work demonstrated that TNFAIP2 activates RAC1 to promote TNBC cell proliferation and migration. However, the mechanism by which TNFAIP2 activates RAC1 is unknown. In this study, we found that TNFAIP2 interacts with IQGAP1 and Integrin β4. Integrin β4 activates RAC1 through TNFAIP2 and IQGAP1 and confers DNA damage-related drug resistance in TNBC. These results indicate that the Integrin β4/TNFAIP2/IQGAP1/RAC1 axis provides potential therapeutic targets to overcome DNA damage-related drug resistance in TNBC.

Full Text